Unlock instant, AI-driven research and patent intelligence for your innovation.

Fusion protein for preparing Abeta (Amyloidbeta-peptide) epitope vaccines, and preparation method and application thereof

A fusion protein and epitope vaccine technology, applied in the field of recombinant fusion protein and its preparation, to improve the effect of humoral immunity and overcome immune tolerance

Inactive Publication Date: 2016-03-23
YUNNAN UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the failure of its phase IIa clinical trial revealed that: Aβ 42 The induced cellular immune response can produce sensitized T cells with central nervous toxicity in the brain of some patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein for preparing Abeta (Amyloidbeta-peptide) epitope vaccines, and preparation method and application thereof
  • Fusion protein for preparing Abeta (Amyloidbeta-peptide) epitope vaccines, and preparation method and application thereof
  • Fusion protein for preparing Abeta (Amyloidbeta-peptide) epitope vaccines, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Embodiment 1: the design of fusion protein

[0055] Fusion protein EcA-PADRE-Aβ for preparing Aβ epitope vaccine designed by the present invention 1-15 (referred to as EPA) consists of Escherichia coli asparaginase EcA at the N-terminal, helper T cell epitope PADRE in the middle and human Aβ at the C-terminal 42 functional B cell epitope Aβ 1-15 It consists of three parts. Among them, the first part EcA is directly connected to the second part PADRE, the second part PADRE is connected to the third part Aβ 1-15 A Linker connection is added in the middle to reduce steric hindrance and facilitate the effective presentation of epitope polypeptides. The structural model of the fusion protein EPA is shown in figure 1 Shown in B.

[0056] In addition, in the implementation process, the present invention has also designed another fusion protein EcA-TTe-Aβ by replacing PADRE with T auxiliary epitope TTe (amino acid sequence such as SEQ ID NO: 17, gene coding sequence such a...

Embodiment 2

[0057] Embodiment 2: Construction and identification of fusion protein EPA expression vector

[0058] 1. EcA, PADRE-Aβ 1-15 Amplification of fusion genes

[0059] The EcA coding gene was amplified by PCR using the plasmid pMD19T-EcA as a template, using primers (see Table 1) SEQIDNO: 11 and SEQIDNO: 12, and introducing restriction sites NcoI and BamHI while designing the primers.

[0060] PADRE-Aβ 1-15 The fusion gene is amplified by direct PCR with primers. At first, primers (see Table 1) SEQIDNO:13 and SEQIDNO:14 are used as templates to amplify the PCR product, and then primers (see Table 1) SEQIDNO:15 and SEQIDNO:16 are used to recover The purified PCR product above was used as a template for the final amplification of PADRE-Aβ 1-15 Fusion gene, when designing primers (see table 1) SEQIDNO:15 and SEQIDNO:16, introduce restriction site BamHI and XhoI simultaneously,

[0061] Table 1: Primer Design

[0062]

[0063] 2. Construction of fusion protein expression vector...

Embodiment 3

[0068] Example 3: Induced expression, extraction, separation, purification and identification of fusion protein EPA in E.coli

[0069] 1. Induced expression of fusion protein in E.coli

[0070] Inoculate the constructed positive BL21(DE3) strain containing the pEPA plasmid into the r In the 2YT liquid medium (1.6% tryptone, 1% yeast extract, 0.5% NaCl, pH=7.0), shake culture at 37°C until OD 600 When it is 0.6-1.0, induce culture with IPTG at a concentration of 1 mmol / L at 25°C for 14 hours. Take 1mL of the bacterial liquid to collect the bacterial cells by centrifugation, resuspend the bacterial cells in the protein electrophoresis sample buffer, boil for 5 minutes, and perform SDS-PAGE detection, and then use Coomassie brilliant blue R-250 staining to observe the purpose, the results (such as Figure 4 Shown in A) The fusion protein with a molecular weight of about 42kDa (theoretical molecular weight is 41657.79Da) was successfully expressed.

[0071] 2. Extraction and se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
purityaaaaaaaaaa
purityaaaaaaaaaa
Login to View More

Abstract

The invention discloses fusion protein for preparing Abeta (Amyloidbeta-peptide) polyvalent epitope vaccines. The fusion protein has three functional structural domains and is prepared from escherichia coli asparaginase II at the N-end, a Th (Helper T Cell) epitope polypeptide at the middle part and an Abeta function B cell epitope polypeptide at the C-end. Based on the Abeta polyvalent epitope vaccines prepared and constructed by the fusion protein provided by the invention, a very strong humoral immune response and a very strong cellular immune response aiming at Abeta can be induced, and an immune response can be induced to shift towards a Th2 direction, the efficiency and the safety which are better than those of traditional antigen protein are expressed, and a foundation is laid for preventing and treating Abeta-based AD (Alzheimers Disease).

Description

technical field [0001] The invention belongs to the field of bioengineering, and relates to a recombinant fusion protein for preparing Aβ multivalent epitope vaccine and a preparation method thereof. More specifically, the present invention provides a technical method and application for improving the immunogenicity of Aβ functional B cell epitope and optimizing the immune characteristics of Aβ vaccine by using genetic engineering technology. Background technique [0002] Alzheimer's disease (AD) is a fatal neurodegenerative disease and the main type of senile dementia. It is clinically characterized by an insidious onset with gradual onset of memory loss, cognitive dysfunction, abnormal behavior, and social impairment. As the disease progresses, the patient gradually loses the ability to live independently, and dies of complications 10 to 20 years after the onset. Suffering from AD not only seriously affects the quality of life of the patient itself, but also brings a hea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N9/82C12N15/62C12N15/70A61K39/00A61K39/385A61P25/28
CPCA61K39/00A61K39/385A61K2039/57A61K2039/6031A61K2039/70C07K14/4711C07K2319/00C12N9/82C12N15/62C12Y305/01001
Inventor 林洁吴洁杨艳曹荣月沈飞彭颜梅
Owner YUNNAN UNIV